Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zosano Pharma Corporation ZSAN


Primary Symbol: ZSANQ

Healthcare Biotechnology
Zosano Pharma Corp is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Zosano Pharma Corp is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Zosano Pharma Corp. Zosano Pharma Corp is a clinical-stage specialty pharmaceutical company. It has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of various indications. The company only operating segment being developing human pharmaceutical products. All the business activities of the firm is functioned through the market of the United States. Its product includes Qtrypta (M207) which is a formulation of zolmitriptan delivered utilizing an Adhesive Dermally-Applied Microarray technology.


EXPM:ZSANQ - Post by User

Zosano Pharma Corporation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(77)
•••
Post by Humaniston Aug 14, 2019 10:59am
84 Views
Post# 30027036

ZOSAN ANNOUNCES IND FILING PHASE 2/3 CLINICAL STUDY

ZOSAN ANNOUNCES IND FILING PHASE 2/3 CLINICAL STUDY

Zosano Pharma (ZSAN) Announces IND Filing to Initiate Phase 2/3 Clinical Study in Cluster Headache

August 14, 2019 9:01 AM EDT   
Zosano Pharma Corporation (NASDAQ: ZSAN) today announced that the Company has submitted an Investigational New Drug (IND) application to the ... 

This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities